参考文献/References:
[1] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary [J]. Acta Neuropathol, 2016, 131(6): 803-820.
[2] Stupp R, Taillibert S, Kanner AA, et al. Maintenance Thera-py with tumor-treating fields plus temozolomide vs temo-zolomide alone for glioblastoma: a randomized clinical trial [J]. Jama, 2015, 314(23): 2535-2543.
[3] Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma [J]. J Clin Oncol, 2009, 27(28): 4733-4740.
[4] Sanai N, Polley MY, Mcdermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas [J]. J Neurosurg, 2011, 115(1): 3-8.
[5] Ogawa S, Tank DW, Menon R, et al. Intrinsic signal changesaccompanying sensory stimulation: functional brain map-ping with magnetic resonance imaging [J]. Proc Nat Acad Sci USA,1992, 89(13): 5951-5955.
[6] Price SJ, Jena R, Burnet NG, et al. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study [J]. AJNR Am J Neuroradiol, 2006, 27(9): 1969.
[7] Berntsen EM, Gulati S, Solheim O, et al. Functional magne-tic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultra-sound-based neuronavigation system: impact on therapeu-tic strategies, extent of resection, and clinical outcome [J]. Neurosurgery, 2010, 67(2): 251-264.
[8] Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts [J]. Neurosurgery, 2007, 61(5): 935-948.
[9] Ulmer JL, Haceinbey L, Mathews VP, et al. Lesion-induced pseudo-dominance at functional magnetic resonance imaging: implications for preoperative assessments [J]. Neurosurgery, 2004, 55(3): 569-579.
[10] Ivanov M, Ciurea AV. Neuronavigation, principles, surgical technique [J]. J Med Life, 2009, 2(1): 29-35.
[11] Risholm P, Golby AJ, Wells W. Multimodal image registra-tion for preoperative planning and image-guided neuro-surgical procedures [J]. Neurosurg Clin N Am, 2011, 22(2): 197-206.
[12] Senft C, Bink A, Franz K, et al. Intraoperative MRI guidanceand extent of resection in glioma surgery: a randomised, controlled trial [J]. Lancet Oncol, 2011, 12(11): 997-1003.
[13] Eljamel S. 5-ALA Fluorescence image guided resection of glioblastoma multiforme: a meta-analysis of the literature[J]. Int J Mol Sci, 2015, 16(5): 10443-10456.
[14] D? Ez VR, Tejada SS, Idoate Gastearena MA, et al. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience [J]. J Neuro-oncol, 2011, 102(1): 105-113.
[15] Valduvieco I, Verger E, Bruna J, et al. Impact of radiothe-rapy delay on survival in glioblastoma [J]. Clin TranslOncol, 2013, 15(4): 278-282.
[16] Sun MZ, Taemin O, Ivan ME, et al. Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma [J]. J Neurosurg, 2015, 122(5): 1-7.
[17] Artzi M, Bokstein F, Blumenthal DT, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study [J]. Eur J Radiol, 2014, 83(7): 1250-1256.
[18] Dhermain F. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches [J]. Chin J Cancer, 2014, 33(1): 16-24.
[19] Tsien CI, Normolle D, Schipper M, et al. Concurrent temo-zolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma [J]. Clin Cancer Res, 2012, 18(1): 273-279.
[20] Brandsma D, Stalpers L, Taal W, et al. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas [J]. Lancet Oncol, 2008, 9(5): 453-461.
[21] Young RJ, Gupta A, Shah AD, et al. MRI perfusion in determining pseudoprogression in patients with glioblastoma[J]. Clin Imaging, 2013, 37(1): 41-49.
[22] Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients [J]. J Clin Oncol,2008, 26(13): 2192-2197.
[23] Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [J]. New Engl J Med, 2000, 343(19): 1350-1354.
[24] Monika EH, Annie-Claire D, Thierry G, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. [J]. N Engl J Med, 2005, 352(10): 997-1003.
[25] van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvantprocarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951 [J]. J Clin Oncol, 2013, 31(3): 344-350.
[26] Wick W, Roth P, Hartmann C, et al. Long-term analysis of the NOA-04 randomized phase Ⅲ trial of sequential radio-chemotherapy of anaplastic glioma with PCV or temozolo-mide [J]. Neuro Oncol, 2016, 18(11): 1529-1537.
[27] Kreisl T N, Kim L, Moore K, et al. Phase Ⅱ trial of single-agent bevacizumab followed by bevacizumab plus irinotecanat tumor progression in recurrent glioblastoma [J]. J Clin Oncol, 2009, 27(5): 740-745.
[28] Chinot OL, Wolfgang W, Warren M, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblas-toma [J]. N Engl J Med, 2014, 370(8): 709-722.
[29] Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma [J]. N Engl J Med, 2014, 370(8): 699-708.
[30] Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase Ⅲ study of radiation therapy with concurrent gefitinibfor newly diagnosed glioblastoma patients [J]. Int J Radiat Oncol, 2013, 85(5): 1206-1211.
[31] Evangelia R, Panayotis S, Stephanos L, . Phase Ⅱ study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment [J]. Clin Cancer Res, 2009, 15(19): 6258-6266.
[32] Ma DJ, Galanis E, Anderson SK, et al. A phase Ⅱ trial of everolimus, temozolomide, and radiotherapy in patients withnewly diagnosed glioblastoma: NCCTG N057K [J]. Neuro Oncol, 2015, 17(9): 1261-1269.
[33] Nghiemphu PL, Wen PY, Lamborn KR, et al. A phaseⅠtrial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblas-toma [J]. Int J Radiat Oncol Biol Phys., 2011, 81(5): 1422-1427.
[34] Fried I, Lossos A, Ben Ami T, et al. Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma [J]. J Neurooncol, 2018, 136(1): 189-195.
[35] Brown CE, Alizadeh D, Starr R, et al. Regression of gliob-lastoma after chimeric antigen receptor T-cell therapy [J]. N Engl J Med, 2016, 375(26): 2561-2569.
[36] Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2 [J]. Mol Ther, 2010, 18(4): 843-851.
[37] Stupp R, Taillibert S, Kanner A, et al. Effect of tumor-treat-ing fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblas-toma: a randomized clinical trial [J]. JAMA, 2017, 318(23): 2306-2316.
[38] Fleissig A, Jenkins V, Catt S, et al. Multidisciplinary teams in cancer care: are they effective in the UK [J]. Lancet Oncol, 2006, 7(11): 935.
[39] Guilfoyle MR, Weerakkody RA, Oswal A, et al. Implemen-tation of neuro-oncology service reconfiguration in accor-dance with NICE guidance provides enhanced clinical care for patients with glioblastoma multiforme [J]. Br J Cancer,2011, 104(12): 1810.